A morpholinyl anthracycline derivative of formula Ant-L-W-Z-RM wherein RM is a radical selected among the groups: wherein r is an integer from 0 to 7; R12 and R13 are, each independently, hydrogen or methyl, and R14 is hydrogen; the wavy line indicates the attachment point in the derivative of formula; Z is null or a peptidic, non peptidic or hybrid - peptidic and non peptidic - linker selected among: wherein one of the two R3 substituents is a tether to Ant, to W or to L, and the other is null; W is null or a group selected among: wherein one of the two R3 substituents is a tether to L, or to Ant when L is null, and the other is null; R10 and R11 are hydrogen; m is an integer from 0 to 3; A is N-CH 3; and R12 and R13 are hydrogen; L is null or a moiety selected among: wherein C 1 -C 6 alkyl is a straight or branched chain; R3 is null or hydrogen, and the wavy line indicates the attachment point to Ant; R9 is null; n is an integer from 0 to 2; Ant is an anthracycline moiety selected from the formulas (IIa), (IIIa), (IVa) and (Va): wherein the wavy line indicates the attachment to the moiety L, or to the group W, or to the linker Z, or to the radical RM; R1 is NH 2; R2 is methyl or hydroxymethyl; R15 is null; or a pharmaceutically acceptable salt thereof. RM is a radical selected among the groups: wherein r is an integer from 0 to 7; R12 and R13 are, each independently, hydrogen or methyl, and R14 is hydrogen; the wavy line indicates the attachment point in the derivative of formula; r is an integer from 0 to 7; R12 and R13 are, each independently, hydrogen or methyl, and R14 is hydrogen; the wavy line indicates the attachment point in the derivative of formula; Z is null or a peptidic, non peptidic or hybrid - peptidic and non peptidic - linker selected among: wherein one of the two R3 substituents is a tether to Ant, to W or to L, and the other is null; W is null or a group selected among: wherein one of the two R3 substituents is a tether to L, or to Ant when L is null, and the other is null; R10 and R11 are hydrogen; m is an integer from 0 to 3; A is N-CH 3; and R12 and R13 are hydrogen; one of the two R3 substituents is a tether to L, or to Ant when L is null, and the other is null; R10 and R11 are hydrogen; m is an integer from 0 to 3; A is N-CH 3; and R12 and R13 are hydrogen; L is null or a moiety selected among: wherein C 1 -C 6 alkyl is a straight or branched chain; R3 is null or hydrogen, and the wavy line indicates the attachment point to Ant; R9 is null; n is an integer from 0 to 2; C 1 -C 6 alkyl is a straight or branched chain; R3 is null or hydrogen, and the wavy line indicates the attachment point to Ant; R9 is null; n is an integer from 0 to 2; Ant is an anthracycline moiety selected from the formulas (IIa), (IIIa), (IVa) and (Va): wherein the wavy line indicates the attachment to the moiety L, or to the group W, or to the linker Z, or to the radical RM; R1 is NH 2; R2 is methyl or hydroxymethyl; R15 is null; or a pharmaceutically acceptable salt thereof. wherein the wavy line indicates the attachment to the moiety L, or to the group W, or to the linker Z, or to the radical RM; R1 is NH 2; R2 is methyl or hydroxymethyl; R15 is null; or a pharmaceutically acceptable salt thereof.